Table 2. Risk for subsequent clinical malaria in asymptomatic children (n = 1856) during the 12 months follow up after the intervention.
| All episodes | High parasite density episodes(>7000 parasites/µl) | |||||
| HRunadjusted(95% CI) | HRadjusteda(95% CI) | HRadjustedb(95% CI) | HRunadjusted(95% CI) | HRadjusteda(95% CI) | HRadjustedb(95% CI) | |
| Total | ||||||
| msp 2 clones | ||||||
| 0 | 0.66(0.37–1.19) | 0.67(0.37–1.20) | 0.62(0.34–1.12) | 0.61(0.31–1.20) | 0.61(0.31–1.21) | 0.56(0.28–1.11) |
| 1* | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| ≥2 | 0.39(0.17–0.91) | 0.43(0.19–0.99) | 0.43(0.19–0.99) | 0.32(0.11–0.90) | 0.36(0.13–1.01) | 0.35(0.13–1.00) |
| Placebo | ||||||
| msp 2 clones | ||||||
| 0 | 0.36(0.15–0.85) | 0.30(0.12–0.73) | NA | 0.34(0.19–0.99) | 0.31(0.10–1.002) | NA |
| 1* | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| ≥2 | 0.07(0.0084–0.58) | 0.066(0.0078–0.56) | NA | 0.11(0.012–0.99) | 0.17(0.01–1.14) | NA |
| SP bimonthly | ||||||
| msp 2 clones | ||||||
| 0 | 1.26(0.31–5.20) | 1.30(0.31–5.38) | NA | 0.87(0.21–3.59) | 0.93(0.23–3.76) | NA |
| 1* | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| ≥2 | 1.11(0.22–5.72) | 1.23(0.24–6.43) | NA | 0.44(0.06–3.06) | 0.50(0.07–3.41) | NA |
| AS+AQ bimonthly | ||||||
| msp 2 clones | ||||||
| 0 | 0.53(0.19–1.51) | 0.53(0.19–1.49) | NA | 0.51(0.16–1.66) | 0.51(0.15–1.71) | NA |
| 1* | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| ≥2 | 0.58(0.14–2.31) | 0.57(0.14–2.30) | NA | 0.59(0.12–2.86) | 0.58(0.11–2.98) | NA |
The AS+AQ monthly group is not included in the table since no parasite positive children developed a clinical episode during follow up.
*
reference group.
a
adjusted for age.
b
adjusted for age and treatment group.
NA not applicable.
No significant deviations from the proportional hazards assumptions were found.